Details of the Drug Combination

General Information of Drug Combination (ID: DC6VOBB)

Drug Combination Name
BREQUINAR MK-4815
Indication
Disease Entry Status REF
DD2 Investigative [1]
Component Drugs BREQUINAR   DMKGM42 MK-4815   DMT9K74
Small molecular drug N.A.
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: DD2
Zero Interaction Potency (ZIP) Score: 9.861
Bliss Independence Score: 12.14
Loewe Additivity Score: 2.469
LHighest Single Agent (HSA) Score: 1.241

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of BREQUINAR
Disease Entry ICD 11 Status REF
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [2]
Acute myeloid leukaemia 2A60 Phase 1/2 [3]
BREQUINAR Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Dihydroorotate dehydrogenase (DHODH) TTLVP78 PYRD_HUMAN Modulator [5]
------------------------------------------------------------------------------------
Indication(s) of MK-4815
Disease Entry ICD 11 Status REF
Malaria 1F40-1F45 Investigative [4]

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 ClinicalTrials.gov (NCT04575038) CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19 (CRISIS2). U.S. National Institutes of Health.
3 ClinicalTrials.gov (NCT03760666) A Study of Brequinar in Subjects With Relapsed/Refractory Acute Myeloid Leukemia. U.S. National Institutes of Health.
4 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
5 DOI: 10.1203/00006450-198807000-00137